Axitinib, a novel anti-angiogenic drug with promising activity in various solid tumors

Current Opinion in Investigational Drugs

Volumn 9, Issue 6, 2008, Pages 658-671

  Choueiri, T K ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABT 869; ANTHRACYCLINE; ANTIHYPERTENSIVE AGENT; AXITINIB; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CP 868596; CYCLOPHOSPHAMIDE; CYTOKINE; DOCETAXEL; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; INDAZOLE DERIVATIVE; IRINOTECAN; OXALIPLATIN; PACLITAXEL; PLACEBO; RABEPRAZOLE; SORAFENIB; SUNITINIB;

ABDOMINAL PAIN; ACUTE GRANULOCYTIC LEUKEMIA; ALOPECIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ASTHENIA; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARCINOMA; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTINUOUS INFUSION; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPHONIA; FATIGUE; FEBRILE NEUTROPENIA; HAND FOOT SYNDROME; HOARSENESS; HUMAN; HYPERTENSION; HYPONATREMIA; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CANCER; KIDNEY CARCINOMA; LIVER FUNCTION TEST; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MESENTERIC VEIN THROMBOSIS; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; NONHUMAN; PANCREAS CANCER; PANCREATITIS; PATENT; PROSTATE CANCER; PROTEINURIA; PRURITUS; RASH; REVIEW; SEIZURE; SIDE EFFECT; SOLID TUMOR; STOMATITIS; STRUCTURE ACTIVITY RELATION; THYROID CANCER; TUMOR XENOGRAFT; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION;

ANGIOGENESIS INHIBITORS; ANIMALS; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; IMIDAZOLES; INDAZOLES; NEOPLASMS; PATENTS AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 44649151405     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (119)

1. 418406 SU-6668 (SUGEN). Fabbro D, Manley PW CURR OPIN INVESTIG DRUGS 2001 2 8 1142-1148
2. 439145 Pharmacia discontinues development of SU-5416. Pharmacia Corp PRESS RELEASE 2002 February 08
3. 439404 Drug development pipeline: SU-5416. SUGEN Inc COMPANY COMMUNICATION 2002 February 12
4. 447394 Characterization of potency and activity of the VEGF/PDGF receptor tyrosine kinase inhibitor AG013736. Hu-Lowe D, Hallin M, Feeley R, Zou H, Rewolinski D, Wickman G, Chen E, Kim Y, Riney S, Reed J, Heller D et al PROC AM ASSOC CANCER RES 2002 43 Abs 5356
5. 447395 Pharmacological activities of AG013736, a small molecule inhibitor of VEGF/PDGR receptor tyrosine kinases. Hu-Lowe D, Heller D, Brekken J, Feeley R, Haines M, Troche G, Kim Y, Herrman M, Batugo M, Vekich S, Kania R et al PROC AM ASSOC CANCER RES 2002 43 Abs 5357
6. 447691 American Association of Cancer Research - 93rd Annual Meeting (Part IX), San Francisco, CA, USA, 6-10 April 2002. Williams L, Mazucco R IDDB MEETING REPORT 2002 April 06-10
7. 496663 AG-013736, a novel VEGFR TK inhibitor, suppresses tumor growth and vascular permeability in human BT474 breast cancer xenografts in nude mice. Wilmes LJ, Hylton N, Wang DH, Fleming L, Gibbs J, Kim Y, Dillon R, Brasch RC, Park JW, Li KL, Henry R et al PROC AM ASSOC CANCER RES 2003 44 Abs 3772
8. 496684 Further characterization of the potent VEGF/PDGF receptor tyrosine kinase inhibitor AG-013736 in preclinical tumor models for its antiangiogenesis and antitumor activity. Wickman G, Hallin M, Amundson K, Acena A, Grazzini M, Dillon R, Herrmann M, Vekich S, Bender S, Shalinsky DR, Hu-Lowe DD PROC AM ASSOC CANCER RES 2003 44 Abs 3780
9. 515699 A phase I study of the VEGF/PDGF receptor tyrosine kinase inhibitor AG-013736 in patients with advanced solid tumors: Safety, pharmacokinetics, and dceMRI. Herbst R, Rugo H, Liu G, Park J, Kies M, Pithavala Y, McShane T, Evelhoch J, Steinfeldt H, Reich S, Freddo J et al CLIN CANCER RES 2003 9 16 Suppl 1 Abs C253
10. 516412 AG-013736, a potent VEGF/PDGF receptor tyrosine kinase inhibitor, is active against lymphoma growth and chemotherapy-induced vasculogenesis. Paul S, Foutz TJ, Calleri A, Gobbi A, Hu-Lowe D, Shalinsky D, Bertolini F BLOOD 2003 102 11 Abs 2397
11. 535175 SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Murray LJ, Abrams TJ, Long KR, Ngai TJ, Olson LM, Hong W, Keast PK, Brassard JA, O'Farrell AM, Cherrington JM, Pryer NK CLIN EXP METASTASIS 2003 20 8 757-766
12. 538169 The biology of VEGF and its receptors. Ferrara N, Gerber HP, LeCouter J NAT MED 2003 9 6 669-676.
13. 542251 Clinical and dynamic imaging results of the first phase I study of AG-013736, an oral anti-angiogenesis agent, in patients (pts) with advanced solid tumors. Rugo HS, Herbst RS, Liu G, Park JW, Kies MS, Pithavala YK, McShane TM, Steinfeldt HM, Reich SD, Wilding G PROC AM SOC CLIN ONCOL 2004 23 2503
14. 553944 Anti-cancer drug discovery and development - Strategic Research Institute's sixth annual summit, Philadelphia, PA, USA, 21-23 July 2004. Zhu Z, Williams B IDDB MEETING REPORT 2004 July 21-23
15. 573089 Phase 2 study of the anti-angiogenesis agent AG-013736 in patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Giles FJ, Steinfeldt H, Bellamy WT, Bycott P, Pithavala Y, Reich SD, List AF BLOOD 2004 104 11 Abs 1813
16. 573518 Pfizer showcases pipeline Pfizer Inc PRESS RELEASE 2004 November 30
17. 574285 Pfizer analyst meeting. Pfizer Inc COMPANY PRESENTATION 2004 November 30
18. 593433 Preclinical activity of ABT-869, a multi-targeted receptor tyrosine kinase inhibitor. Albert DH, Tapang P, Magoc TJ, Pease LJ, Reuter DR, Li J, Guo J, Ghoreishi-Haack NS, Brooks JV, Bukofzer GT, Davidsen SK et al PROC AM ASSOC CANCER RES 2005 46 Abs 676
19. 595750 Significant enhancement of anti-tumor efficacy of VEGF/PDGF receptor tyrosine kinase inhibitor AG-013736 in combination with docetaxel in chemo-refractory and/or orthotopic xenograft tumor models in mice. Hu-Lowe DD, Grazzini ML PROC AM ASSOC CANCER RES 2005 46 Abs 2032
20. 595956 American Association for Cancer Research - 96th Annual Meeting (part V) - overnight report, Anaheim, CA, USA, 16-20 April 2005. Collins T IDDB MEETING REPORT 2005 April 16-20
21. 596111 PK/PD modeling based on mouse xenograft tumor growth inhibition and the correlation to clinical exposure for VEGF/PDGF receptor tyrosine kinase inhibitor AG-013736. Yamazaki S, Grazzini ML, Romero D, Amundson K, Pithavala Y, Hu-Lowe DD PROC AM ASSOC CANCER RES 2005 46 Abs 3003
22. 596245 American Association for Cancer Research - 96th Annual Meeting (part VIII) - overnight report, Anaheim, CA, USA, 16-20 April 2005. Davies J IDDB MEETING REPORT 2005 April 16-20
23. 597067 American Association for Cancer Research - 96th Annual Meeting (Part XII), Anaheim, CA, USA, 16-20 April 2005 Phillips T IDDB MEETING REPORT 2005 April 16-20
24. 601823 AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC). Rini B, Rixe O, Bukowski R, Michaelson MD, Wilding G, Hudes G, Bolte O, Steinfeldt H, Reich SD, Motzer R PROC AM SOC CLIN ONCOL 2005 24 Abs 4509
25. 604041 Surrogate markers of activity of AG-013736, a multi-target tyrosine kinase receptor inhibitor, in metastatic renal cell cancer (RCC). Rixe O, Meric J, Bloch J, Gentile A, Mouawad R, Adam V, Buthiau D, Khayat D PROC AM SOC CLIN ONCOL 2005 24 Abs 3003
26. 637280 Pfizer oncology pipeline. Pfizer inc COMPANY PUBLICATION 2005 November 25
27. 659675 Combined effects of VEGF/PDGF receptor tyrosine kinase inhibitors plus fractionated radiation on DU145 prostate carcinoma vasculature and oxygenation. Fenton BM, Paoni SF PROC AM ASSOC CANCER RES 2006 47 Abs 973
28. 671080 A phase II study of axitinib (AG-013736), a potent inhibitor of VEGFRs, in patients with advanced thyroid cancer. Kim S PROC AM SOC CLIN ONCOL 2006 25 Abs 5529
29. 672630 American Society of Clinical Oncology - 42nd Annual Meeting (part XI) - overnight report, 02-06 June 2006, Atlanta, GA, USA. Cleverley J, Searle B, Chan D IDDB MEETING REPORT 2006 June 02-06
30. 677553 NCT00219557: AG-013736 in combination with gemcitabine versus gemcitabine alone for patients with metastatic pancreatic cancer. Pfizer CLINICALTRIALS.GOV 2005 June 16
31. 681749 NCT00282048: Phase 2 study of AG-013736 in patients with refractory metastatic renal cell cancer. Pfizer CLINICALTRIALS.GOV 2006 July 25
32. 681754 NCT00076024: AG-013736 in combination with docetaxel versus docetaxel alone for patients with metastatic breast cancer. CLINICALTRIALS.GOV 2006 July 25
33. 683633 NCT00176748 treatment for patients with metastatic thyroid cancer. Pfizer INTERNET SITE 2005 September
34. 685691 Study summary - 2005-0474 - a phase I study of ABT-869 in patients with refractory or relapsed acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS). MD Anderson Cancer Center COMPANY WORLD WIDE WEB SITE 2006 August 23
35. 738678 Antiangiogenic inhibitor axitinib (AG-013736) renders significant growth inhibition of bevacizumab-refractory xenograft tumors. Hu-Lowe D, Grazzini M, Amundon K, Wickman G, Qiu M, Kang D, Los G, Chen E EUR J CANCER 2006 4 12 Abs 71
36. 757356 Pfizer pipeline Pfizer Inc COMPANY WORLD WIDE WEB SITE 2008 December 20
37. 760283 NCT00386555: A study in patients with advanced non-small cell lung cancer using new agents with and without docetaxel. CLINICALTRIALS.GOV 2007
38. 764640 Pfizer's sutent receives FDA approval to include new first-line advanced kidney cancer data in label. Pfizer Inc PRESS RELEASE 2007 February 08
39. 766499 Onyx Pharmaceuticals reports fourth quarter and year-end 2006 financial results. Onyx Pharmaceuticals Inc PRESS RELEASE 2007 February 15
40. 767688 IDM Pharma raises $12.8 million in private placement. IDM Pharma Inc PRESS RELEASE 2007 February 21
41. 774838 Pfizer Japan's new drugs in the R& D pipeline. PHARMA JPN 2007 2032 March 12
42. 782900 Modulation of the anti-tumor effect of metronomic cyclophosphamide by the anti-angiogenic agent axitinib (AG-013736). Ma J, Waxman DJ AM ASSOC CANCER RES ANN MEET 2007 98 Abs 4635
43. 796219 A randomized phase II study of axitinib (AG-013736) and gemcitabine versus gemcitabine in advanced pancreatic cancer, preceded by a phase I component. Spano J-P AM SOC CLIN ONCOL 2007 43 Abs 4551
44. 797542 A phase II study of axitinib (AG-013736 [AG]) in patients (pts) with advanced thyroid cancers. Cohen EEW AM SOC CLIN ONCOL 2007 43 Abs 6008
45. 797688 Axitinib (AG-013736; AG) in patients (pts) with metastatic renal cell cancer (RCC) refractory to sorafenib. Rini BI AM SOC CLIN ONCOL 2007 43 Abs 5032
46. 797690 Phase II trial of sunitinib in bevacizumab-refractory metastatic renal cell carcinoma (mRCC): Updated results and analysis of circulating biomarkers George DJ AM SOC CLIN ONCOL 2007 43rd Abs 5035
47. 798523 Efficacy and safety of axitinib (AG-013736; AG) in patients (pts) with advanced non-small cell lung cancer (NSCLC): A phase II trial. Schiller JH AM SOC CLIN ONCOL 2007 43 Abs 7507
48. 798524 A randomized, double-blind phase II study of the oral tyrosine kinase inhibitor (TKI) axitinib (AG-013736) in combination with docetaxel (DOC) compared to DOC plus placebo (PL) in metastatic breast cancer (MBC). Rugo HS AM SOC CLIN ONCOL 2007 43 Abs 1003
49. 799090 NCT00471146: Randomized study of gemcitabine plus AG-013736 versus gemcitabine for advanced pancreatic cancer. CLINICALTRIALS.GOV 2007 May 07
50. 801272 American Society of Clinical Oncology - 43rd Annual Meeting (part III) - overnight report, translating research into practice, Chicago, IL, USA, 1-5 June 2007. Kibble A IDDB MEETING REPORT 2007 June 1-5
51. 801663 New data show Pfizer's axitinib prolonged overall survival in advanced pancreatic cancer when combined with standard of care chemotherapy. Pfizer Inc PRESS RELEASE 2007 June 04
52. 808616 Genentech to codevelop Abbott's cancer compounds. Abbott PRESS RELEASE 2007 June 26
53. 814377 Gastrointestinal Cancer - Ninth World Congress, Barcelona, Spain, 27-30 June 2007. Jackson C IDDB MEETING REPORT 2007 June 27-30
54. 819943 Pfizer says growth in phase II portfolio supports goal of tripling phase III portfolio by 2009. Pfizer Inc PRESS RELEASE 2007 August 06
55. 819952 Kidney and Bladder Cancer - Fourth International Congress (part II), tyrosine kinase inhibitors for non-clear cell renal cell carcinoma, Orlando, FL, USA, 3-5 August 2007. Choueiri T IDDB MEETING REPORT 2007 August 03-05
56. 819965 Pfizer pipeline. Pfizer Inc COMPANY WORLD WIDE WEB SITE 2007 July 31
57. 820091 NCT00076011: Anti-angiogenesis agent AG-013736 in patients with metastatic renal cell carcinoma. Pfizer CLINICALTRIALS.GOV 2007 July 30
58. 826225 Product update: New product: Sutent. Pfizer Inc MIMS (LONDON) 2007 October 01
59. 843107 Axitinib (AG-013736; AG) in combination with paclitaxel (P)/carboplatin (C) in patients (pts) with advanced solid tumors. Cohen B, Kozloff F, Starr A, Pithavala Y, Tortorici M, Liau F, Tarazi JC, Olszanski J AACR-NCI-EORTC INT CONGRESS 2007 19 Abs A157
60. 846096 A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Fiedler W, Serve H, Dohner H, Schwittay M, Ottmann OG, O'Farrell AM, Bello CL, Allred R, Manning WC, Cherrington JM, Louie SG et al BLOOD 2005 105 3 986-993
61. 852707 FDA approves Nexavar for hepatocellular carcinoma. Bayer HealthCare Pharmaceuticals; Onyx Pharmaceuticals Inc PRESS RELEASE 2007 November 19
62. 870794 Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: A phase II study Rixe O, Bukowski RM, Michaelson MD, Wilding G, Hudes GR, Bolte O, Motzer RJ, Bycott P, Liau KF, Freddo J, Trask PC et al LANCET ONCOL 2007 8 11 975-984 • Data showing an impressive activity of axitinib in metastatic RCC patients failing immunotherapy are discussed. The time to progression of 15.7 months is the longest reported to date in this patient population.
63. 870806 The addition of AG-013736 to fractionated radiation improves tumor response without functionally normalizing the tumor vasculature. Fenton BM, Paoni SF CANCER RES 2008 67 20 9921-9928
64. 870807 Phase 2 studies of sunitinib and AG013736 in patients with cytokine-refractory renal cell carcinoma. George DJ CLIN CANCER RES 2007 13 2 753s-757s
65. 870808 AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging. Wilmes LJ, Pallavicini MG, Fleming LM, Gibbs J, Wang D, Li KL, Partridge SC, Henry RG, Shalinsky DR, Hu-Lowe D, Park JW et al MAGN RESON IMAGING 2007 25 3 319-327
66. 870810 The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Giles FJ, Bellamy WT, Estrov Z, O'Brien SM, Verstovsek S, Ravandi F, Beran M, Bycott P, Pithavala Y, Steinfeldt H, Reich SD et al LEUK RES 2006 30 7 801-811
67. 870811 Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: Pharmacokinetic and clinical results Rugo HS, Herbst RS, Liu G, Park JW, Kies MS, Steinfeldt HM, Pithavala YK, Reich SD, Freddo JL, Wilding G J CLIN ONCOL 2005 23 24 5474-5483 • A phase I clinical trial that demonstrated the pharmacokinetics and safety of axitinib in patients with advanced solid tumors and identified the dose for phase II clinical testing.
68. 870812 Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: Results from a phase I study Liu G, Rugo HS, Wilding G, McShane TM, Evelhoch JL, Ng C, Jackson E, Kelcz F, Yeh BM, Lee FT Jr, Charnsangavej C et al J CLIN ONCOL 2005 23 24 5464-5473
69. 870814 Inhibition of phosphorylation of the CSF-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors. Giuo J, McCall JO, Marcotte PA, Glaser KB PROC AM ASSOC CANCER RES 2005 96 Abs 4568
70. 870815 AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC). Rini B, Rixe O, Bukowski R, Michaelson MD, Wilding G, Hudes G, Bolte O, Steinfeldt H, Reich SD, Motzer R J CLIN ONCOL 2005 23 16 S4509
71. 870816 A phase I/II study of AG-013736, an oral anti-angiogenesis agent, in combination with docetaxel in patients (pts) with metastatic breast cancer (MBC). Rugo HS, Stopeck A, Badorf A, Pithavala YK, Steinfeldt HM BREAST CANCER RES TREAT 2005 94 S1 S62
72. 870818 Clinical and dynamic imaging results of the first phase I study of AG-013736, an oral anti-angiogenesis agent, in patients (pts) with advanced solid tumors. Rugo HS, Herbst RS, Liu G, Park JW, Kies MS, Pithavala YK, McShane TM, Steinfeldt HM, Reich SD, Wilding G J CLIN ONCOL 2004 22 14 S2503
73. 871432 Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma. Zhu AX CANCER 2008 112 2 250-259
74. 877095 Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib. Ma J, Waxman DJ MOL CANCER THER 2008 7 1 79-89
75. 889603 Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. Hicklin DJ, Ellis LM J CLIN ONOL 2005 23 5 1011-1027
76. 889620 Overexpression of the colony-stimulating factor (CSF-1) and/or its receptor c-Fms in mammary glands of transgenic mice results in hyperplasia and tumor formation. Kirma N, Luthra R, Jones J, Liu YG, Nair HB, Mandava U, Tekmal RR CANCER RES 2004 64 12 4162-4170
77. 889623 The current role of angiogenesis inhibitors in the treatment of renal cell carcinoma. Choueiri TK, Bukowski RM, Rini BI SEMIN ONCOL 2006 33 5 596-606
78. 889627 Sunitinib, a multitargeted tyrosine kinase inhibitor, in the management of gastrointestinal stromal tumor. GEORGE S CURR ONCOL REP 2007 9 4 323-327
79. 889889 WO-2006048745: Methods for preparing indazole compounds. Srinivasan B, Dagnino R Jr, Ouellette M, Shi A, Tian B, Zook Q, Edward S WORLD PATENT 2006 May 11
80. 889893 WO-00102369: Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use. Kania RS, Bender SL, Borchardt AJ, Braganza JF, Cripps SJ, Hua Y, Johnson MD, Johnson TO Jr, Luu HT, Palmer CL, Reich SH et al WORLD PATENT 2001 January 11
81. 892619 WO-2006048744: Methods of preparing indazole compounds. Ewanicki BL, Flahive EJ, Kasparian AJ, Mitchell MB, Perry MD, O'Neill-Sla Wecki SA, Sach NW, Saenz JE, Shi B, Stankovic NS Srirangam JK et al WORLD PATENT 2006 May 11
82. 892766 NCT00454649: Investigational agent AG-013736 in combinations with standard of care treatments for patient's with advanced solid tumor. Pfizer Inc CLINICALTRIALS.GOV 2008 April 03
83. 892768 NCT00447005: A phase 1 study of AG-013736 (axitinib) in Japanese patients with advanced solid tumors. CLINICALTRIALS.GOV 2008 April 03
84. 131I treatment. CLINICALTRIALS. GOV 2008 April 03
85. 131I-refractory metastatic or unresectable locally-advanced papillary, follicular, or hurthle-cell thyroid cancer who are also refractory to, or intolerant of, or have clinical contraindication to, doxorubicin treatment. CLINICALTRIALS.GOV 2008 April 03
86. 893454 NCT00569946: Phase 2 study Of AG-013736 as second-line treatment in patients with metastatic renal cell cancer. CLINICALTRIALS.GOV 2008 April 07
87. 893558 NCT00600821: Randomized phase 2 trial of AG013736 or bevacizumab in combination with paclitaxel and carboplatin as first line treatment for patients with advanced non small cell lung cancer. CLINICALTRIALS.GOV 2008 April 07
88. 893671 NCT00071006: Phase 2 study of AG-013736 in patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome. CLINICALTRIALS.GOV 2008 April 07
89. 893694 SAIC awarded DIA intelligence analysis contract. SAIC PRESS RELEASE 2008 April 07
90. 893804 NCT00094107: Anti-angiogenesis agent AG-013736 in patients with metastatic melanoma. CLINICALTRIALS.GOV 2008 April 07
91. 893817 NCT00460603: Phase 2 study with AG-013736 combined with chemotherapy and bevacizumab in patients with metastatic colorectal cancer. CLINICALTRIALS.GOV 2008 April 07
92. 893837 NCT00615056: A study combining FOLFOX or FOLFIRI with AG-013736 or avastin in patients with metastatic colorectal cancer after failure of one first line regimen. CLINICALTRIALS.GOV 2008 April 07
93. 895098 The nature and action of granulocyte-macrophage colony stimulating factors. Burgess AW, Metcalf D BLOOD 1980 56 6 947-958
94. 896034 Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Lee JC, Chow NH, Wang ST, Huang SM EUR J CANCER 2000 36 6 748-753
95. 896201 Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis and proliferation of human colon cancer. Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM CANCER RES 1995 55 18 3964-3968
96. 896204 Significance of vessel count and vascular endothelial growth factor and its receptor (KDR) in intestinal-type gastric cancer. Takahashi Y, Cleary KR, Mai M, Kitadai Y, Bucana CD, Ellis LM CLIN CANCER RES 1996 2 10 1679-1684
97. 896205 Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Maeda K, Chung YS, Ogawa Y, Takatsuka S, Kang SM, Ogawa M, Sawada T, Sowa M CANCER 1996 77 5 858-863
98. 896208 Expression of two angiogenic factors, vascular endothelial growth factor and platelet-derived endothelial cell growth factor in human pancreatic cancer, and its relationship to angiogenesis. Fujimoto K, Hosotani R, Wada M, Lee JU, Koshiba T, Miyamoto Y, Tsuji S, Nakajima S, Doi R, Imamura M EUR J CANCER 1998 34 9 1439-1447
99. 896211 Prognostic significance of angiogenesis in human pancreatic cancer. Ikeda N, Adachi M, Taki T, Huang C, Hashida H, Takabayashi A, Sho M, Nakajima Y, Kanehiro H, Hisanaga M, Nakano H et al BR J CANCER 1999 79 9-10 1553-1563
100. 896214 Combined vascular endothelial growth factor and TP53 status predicts poor response to tamoxifen therapy in estrogen receptor-positive advanced breast cancer. Berns EM, Klijn JG, Look MP, Grebenchtchikov N, Vossen R, Peters H, Geurts-Moespot A, Portengen H, van Staveren IL, Meijer-van Gelder ME, Foekens JA et al CLIN CANCER RES 2003 9 4 1253-1258
101. 896216 The prognostic value of vascular endothelial growth factor in 574 node-negative breast cancer patients who did not receive adjuvant systemic therapy. Manders P, Beex LV, Tjan-Heijnen VC, Geurts-Moespot J, Van Tienoven TH, Foekens JA, Sweep CG, BR J CANCER 2002 87 7 772-778
102. 896220 Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on cancer and leukemia group B 9480. George DJ, Halabi S, Shepard TF, Vogelzang NJ, Hayes DF, Small EJ, Kantoff PW CLIN CANCER RES 2001 7 7 1932-1936
103. 896223 Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: A prospective study. Fontanini G, Lucchi M, Vignati S, Mussi A, Ciardiello F, De Laurentiis M, De Placido S, Basolo F, Angeletti CA, Bevilacqua G J NATL CANCER INST 1997 89 12 881-886
104. 896226 Differential expression of vascular endothelial growth factor-A isoforms at different stages of melanoma progression. Gorski DH, Leal AD, Goydos JS J AM COLL SURG 2003 197 3 408-418
105. 896244 Vascular remodeling tumors that recur during chronic suppression of angiogenesis. Huang J, Soffer SZ, Kim ES, McCrudden KW, Huang J, New T, Manley CA, Middlesworth W, O'Toole K, Yamashiro DJ, Kandel JJ MOL CANCER RES 2004 2 1 36-42
106. 896355 VEGF inhibition and renal thrombotic microangiopathy. Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J, Richardson C, Kopp JB, Kabir MG, Backx PH, Quaggin SE et al N ENGL J MED 2008 358 11 1129-1136
107. 896357 Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, Woulfe K, Pravda E, Cassiola F, Desai J, Chen MH et al LANCET 2007 370 9604 2011-2019
108. 896363 Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, Bohlen P, Kerbel RS J CLIN INVEST 2000 105 8 R15-R24
109. 896366 The activated macrophage colony-stimulating factor (CSF-1) receptor as a predictor of poor outcome in advanced epithelial ovarian carcinoma. Toy EP, Chambers JT, Kacinski BM, Flick MB, Chamber SK GYNECOL ONCOL 2001 80 2 194-200,
110. 896369 CSF-1 and its receptor in ovarian, endometrial and breast cancer. Kacinski BM ANN MED 1995 27 1 79-85
111. 899165 Treatment discontinuations, dose reductions and interruptions for angiogenesis inhibitor therapies in patients with metastatic renal cell carcinoma (mRCC). Brick AJ, McDermott D, Clement J AM ASSOC CANCER RES ANN MEET 2008 99 April 13
112. 900640 Colony-stimulating factor-1 and c-fms expression in human endometrial tissues and placenta during the menstrual cycle and early pregnancy. Kauma SW, Aukerman SL, Eierman D, Turner T J CLIN ENDOCRINOL METAB 1991 73 4 746-751
113. 900701 Safety and anti-tumor activity of sorafenib (Nexavar) in combination with other anti-cancer agents: A review of clinical trials. Takimoto CH, Awada A CANCER CHEMOTHER PHARMACOL 2008 61 4 535-548
114. 901718 Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. Kerbel RS BIOASSAYS 1991 13 1 31-36
115. 902821 Vascular endothelial growth factor is a secreted angiogenic mitogen. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N SCIENCE 1989 246 4935 1306-1309
116. 902822 VEGF-receptor signal transduction. Cross MJ, Dixelius J, Matsumoto T, Claesson-Welsh L TRENDS BIOCHEM SCI 2003 28 9 488-494.
117. 902823 Sunitinib: A novel tyrosine kinase inhibitor. A brief review of its therapeutic potential in the treatment of renal carcinoma and gastrointestinal stromal tumors (GIST). Le Tourneau C, Raymond E, Faivre S THER CLIN RISK MANAG 2007 3 2 341-348
118. 902856 Acquired drug resistance driven by tumor cell genetic instability: Circumvention by direct acting anti-angiogenic vascular targeting agents. Kerbel RS DNA ALTERATIONS IN CANCER: GENETIC AND EPIGENETIC CHANGES (ED: EHRLICH M) 2000 Biotechniques Books, Natick, MA, USA 489-501
119. 903055 Factors associated with outcome in patients with advanced renal cell carcinoma in the era of antiangiogenics agents. Choueiri TK CLIN GENITOURINARY CANCER 2008 6 1 15-20.